Melanotan 2: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 12 sources cited
Overview
Melanotan-2 (MT-2) is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that produces skin tanning, enhances sexual arousal, and suppresses appetite through broad melanocortin receptor activation. It is one of the most widely used research peptides globally, known for its potent multi-receptor activity across MC1R through MC5R. Unlike Melanotan-1, its non-selective binding profile produces a diverse range of physiological effects beyond melanogenesis.
Mechanism of Action
Melanotan-2 is a cyclic heptapeptide (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) designed with a lactam bridge between positions 5 and 10 that confers exceptional metabolic stability and receptor binding potency compared to linear α-MSH. Its mechanism is multifaceted due to non-selective activation of melanocortin receptors MC1R through MC5R, each mediating distinct physiological responses. At MC1R on melanocytes, MT-2 triggers the same cAMP/PKA/MITF cascade as Melanotan-1, driving eumelanin synthesis and producing progressive skin darkening. This occurs even without UV exposure, though concurrent moderate UV exposure significantly accelerates and deepens the tanning response by providing the oxidative stress signals that synergize with melanocortin signaling. At MC4R in the hypothalamus, MT-2 produces two clinically significant effects. First, it activates pro-opiomelanocortin (POMC) neurons in the arcuate nucleus, reducing appetite and food intake through the same anorexigenic pathway targeted by setmelanotide (an FDA-approved MC4R agonist for genetic obesity). Second, MC4R activation in the paraventricular nucleus triggers descending autonomic pathways to the sacral spinal cord, promoting penile erection in males and genital arousal in females. This erectogenic effect is centrally mediated — it originates in the brain rather than acting on peripheral vasculature like PDE5 inhibitors, making it effective even in cases of psychogenic erectile dysfunction. At MC3R, MT-2 modulates energy homeostasis and fat partitioning, contributing to favorable body composition changes observed during use. MC5R activation affects exocrine gland function, potentially altering sebum production. The peptide also demonstrates anxiolytic properties in preclinical models, likely through melanocortin modulation of limbic circuits. The cyclic structure gives MT-2 a half-life of approximately 1–2 hours after subcutaneous injection, but its biological effects (particularly melanogenesis) persist far longer due to downstream gene expression changes that continue for days after receptor activation. This pharmacokinetic-pharmacodynamic disconnect allows for infrequent dosing during maintenance phases.
Melanotan 2 Benefits: What the Research Shows
- Dorr et al. (1996) in Life Sciences ran a pilot phase I study in 3 healthy men; two showed increased skin pigmentation after 5 low subcutaneous doses, the first human evidence of tanning activity
- A landmark study in the Journal of Urology (1998) showed that MT-2 induced erections in 8 of 10 men with psychogenic erectile dysfunction in a double-blind, placebo-controlled crossover trial
- Wessells et al. (2000) reported in the International Journal of Impotence Research that MT-2 produced erections without sexual stimulation in 17 of 20 men with psychogenic or organic erectile dysfunction and increased reported sexual desire; rat studies place the site of action in the brain and spinal cord
- A review published in Peptides (2005) reported that MT-2 increased sexual desire and genital arousal in women as well as erectile activity in men; the controlled trial in premenopausal women with female sexual arousal disorder used its derivative bremelanotide (PT-141)
- Preclinical studies show MT-2 reduces food intake and body weight gain in rodent models through central melanocortin receptor signaling (Endocrinology, 2007)
- Van der Klaauw et al. (2016) showed that people with MC4R deficiency have altered food preferences, evidence that central melanocortin signaling shapes eating behavior in humans, the pathway through which MT-2 is thought to suppress appetite
Melanotan 2 Dosage
- Loading phase: 0.25 mg subcutaneous injection daily for the first 2–3 days to assess tolerance, then increase to 0.5–1.0 mg daily
- Standard loading protocol: 0.5 mg daily for 14–21 days until desired tan is achieved
- Maintenance: 0.5–1.0 mg twice weekly to sustain pigmentation
- For sexual enhancement (acute use): 0.5–1.0 mg administered 2–4 hours before anticipated activity
- Best injected in the evening — nausea is most common in the first hour and sleep helps bypass discomfort
- Combine with 10–20 minutes of UV exposure 4–6 hours post-injection during loading phase for optimal tanning
- Some users pre-treat with an antihistamine (to reduce flushing) or antiemetic (to reduce nausea) for the first several doses
- Maximum suggested research dose: 1.0 mg per day; exceeding this does not accelerate results and increases side effects
- Typical full cycle: 3–4 weeks loading, then indefinite maintenance at reduced frequency
- Allow at least 4–6 weeks between loading cycles if taking breaks
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Melanotan 2 Side Effects & Safety
Known Side Effects
- Nausea — the most frequently reported side effect in the early clinical studies, where it was mild at most dose levels and severe in about 13% of men at 0.025 mg/kg; typically dose-dependent, and users report that it diminishes with continued use
- Facial flushing — transient warmth and redness lasting 30–90 minutes post-injection, caused by peripheral vasodilation via melanocortin receptors on vascular endothelium
- Spontaneous or prolonged erections — can occur 1–5 hours post-injection; priapism is rare but has been reported and constitutes a medical emergency
- Appetite suppression — significant reduction in hunger lasting 12–24 hours post-dose; can lead to unintended weight loss during loading phases
- Darkening of existing moles, freckles, and nevi — requires dermatological monitoring; new nevi formation has been reported in case studies
- Fatigue and yawning — commonly reported 30–60 minutes post-injection, likely mediated by central melanocortin effects
- Injection site soreness — mild localized pain or redness that resolves within hours
- Mood changes — some users report mild euphoria or increased sociability, while others note irritability during initial loading
Safety Profile
Melanotan-2 is an unregulated research peptide with no FDA or EMA approval, and its safety profile is derived primarily from small clinical studies and extensive anecdotal community reporting rather than large-scale trials. The FDA has flagged it as a bulk drug substance that may present significant safety risks, and several national health agencies have warned against its use. The most significant safety concern is dermatological: MT-2 stimulates all melanocytes, including those in preexisting nevi, and there are case reports of atypical mole changes, melanoma in situ and invasive melanoma diagnosed during or shortly after MT-2 use, though causation has not been established. A baseline dermatological exam and regular skin checks every 6 months are strongly recommended. Individuals with a personal or family history of melanoma, dysplastic nevus syndrome, or numerous atypical moles should avoid MT-2 entirely. The erectogenic effects carry a small but real risk of priapism — persistent erection lasting more than 4 hours requires emergency medical intervention. Cardiovascular effects in the small clinical studies were mild (flushing), but case reports describe serious reactions, including a racing heart, muscle breakdown (rhabdomyolysis) and kidney injury after a 6 mg injection, and posterior reversible encephalopathy syndrome; those with uncontrolled hypertension should exercise caution. Because MT-2 is predominantly sourced from unregulated suppliers, purity and sterility are significant concerns — sourcing from third-party tested suppliers is essential. Drug interactions have not been studied, and combining with PDE5 inhibitors (sildenafil, tadalafil) may increase priapism risk.
What to Expect
Days 1–3: Nausea and facial flushing are common within 30–60 minutes of injection. Some users experience yawning, fatigue, or spontaneous erections. No visible tanning yet. Start at 0.25 mg to gauge response. Days 4–7: Nausea typically subsides by day 4–5 as the body acclimates. Existing freckles and moles begin to darken noticeably. A subtle warmth to skin tone may appear, especially with some UV exposure. Appetite suppression becomes apparent. Weeks 2–3: Visible tan develops and deepens progressively. The color tends toward a natural brown-olive tone rather than orange. Sexual effects (increased libido, stronger erections) are consistently reported. Appetite remains suppressed; some users note 2–4 lbs of weight loss. Weeks 4+: Tan is fully established and can be maintained with twice-weekly dosing. Sexual enhancement effects persist at maintenance doses. After cessation, the tan fades over 4–8 weeks depending on sun exposure and skin turnover rate. Mole darkening gradually reverses but should be monitored.
Common Stacks
PT-141
PT-141 (bremelanotide) is derived from MT-2 and acts on the same MC4R pathway for sexual enhancement; some users alternate between the two for targeted sexual versus tanning effects
GHK-Cu
GHK-Cu supports skin quality, collagen production, and repair, complementing the pigmentation effects of MT-2 with improved skin texture and anti-aging benefits
BPC-157
BPC-157's systemic healing and anti-inflammatory effects support overall skin health and may mitigate minor injection site irritation
Melanotan 1
Some protocols layer MT-1 for its MC1R selectivity to deepen the eumelanin response while using MT-2 at lower doses for the multi-receptor benefits
Storage & Handling
Store lyophilized (freeze-dried) powder at -20°C for up to 24 months or at 2–8°C for up to 12 months. Reconstitute with bacteriostatic water — typically 1–2 mL per 10 mg vial for convenient dosing. After reconstitution, store refrigerated at 2–8°C and use within 4–6 weeks. Do not freeze reconstituted solution. Protect from light. MT-2 is relatively stable as a cyclic peptide, but contamination from non-sterile technique is the primary risk — always use alcohol swabs and fresh syringes.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996.
- Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998.
- Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000.
- Wessells H, Hruby VJ, Hackett J, et al. Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience. 2003.
- Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005.
- Habbema L, Halk AB, Neumann M, et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017.
- Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014.
- Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012.
- Mallory CW, Lopategui DM, Cordon BH. Melanotan Tanning Injection: A Rare Cause of Priapism. Sex Med. 2021.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.
- Glavas MM, Joachim SE, Draper SJ, et al. Melanocortinergic activation by melanotan II inhibits feeding and increases uncoupling protein 1 messenger ribonucleic acid in the developing rat. Endocrinology. 2007.
- van der Klaauw AA, Keogh JM, Henning E, et al. Divergent effects of central melanocortin signalling on fat and sucrose preference in humans. Nat Commun. 2016.
Related Peptides
Track Melanotan 2 in Your Protocol
Log your Melanotan 2 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free